|
22 Companies |
|
29 Products |
|
29 Products |
|
31 Mechanisms of Action |
|
1 Trial |
|
87 News |
|
| 12» |
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Grant: Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer (clinicaltrials.gov) - Aug 16, 2018
P2, N=60, Completed, Sponsor: Montefiore Medical Center
Active, not recruiting --> Completed
- | vatalanib (PTK787) / Novartis, Bayer
Trial completion, Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2018
P1, N=96, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
- | Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 11, 2017
P2, N=252, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - May 25, 2017
P1, N=7, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Active, not recruiting --> Completed | N=70 --> 7 | Trial primary completion date: Jun 2016 --> Nov 2010
- |||| Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Trial primary completion date: TELECAST: Telotristat Etiprate for Carcinoid Syndrome Therapy (clinicaltrials.gov) - Apr 4, 2017
P3, N=76, Completed, Sponsor: Lexicon Pharmaceuticals
Active, not recruiting --> Completed | N=70 --> 7 | Trial primary completion date: Jun 2016 --> Nov 2010 Trial primary completion date: Mar 2016 --> Oct 2015
- | vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 22, 2017
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Mar 2016 --> Oct 2015 Trial primary completion date: Dec 2016 --> Dec 2017
- | Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Mar 10, 2017
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Jun 2016 --> Sep 2017
- | Oclaiz (octreotide subcutaneous depot) / Camurus
Trial completion, Enrollment change: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Oct 11, 2016
P2, N=12, Completed, Sponsor: Camurus AB
Trial primary completion date: Jun 2016 --> Sep 2017 Active, not recruiting --> Completed | N=24 --> 12
- Trial completion: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (clinicaltrials.gov) - Aug 15, 2016
P2, N=7, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | N=24 --> 12 Terminated --> Completed
- NN1213 / Novo Nordisk
Trial completion, Enrollment change, Metastases: Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors (clinicaltrials.gov) - Jun 21, 2016
P1, N=27, Completed, Sponsor: O'Dorisio, M S
Terminated --> Completed Recruiting --> Completed | N=35 --> 27
- | Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 13, 2016
P1, N=19, Completed, Sponsor: University of Southern California
Recruiting --> Completed | N=35 --> 27 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Surgery, Metastases: Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery (clinicaltrials.gov) - May 31, 2016
P2, N=20, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Trial primary completion date, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - May 13, 2016
P1, N=27, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Apr 21, 2016
P1, N=70, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014 Trial primary completion date: Jun 2015 --> Jun 2016
- ||||||| Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Trial completion, Enrollment change: TELECAST: Telotristat Etiprate for Carcinoid Syndrome Therapy (clinicaltrials.gov) - Apr 8, 2016
P3, N=76, Completed, Sponsor: Lexicon Pharmaceuticals
Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed | N=100 --> 76
- ||||||| Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Trial completion, Enrollment change: TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) (clinicaltrials.gov) - Apr 7, 2016
P3, N=135, Completed, Sponsor: Lexicon Pharmaceuticals
Active, not recruiting --> Completed | N=100 --> 76 Active, not recruiting --> Completed | N=105 --> 135
- vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 16, 2016
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | N=105 --> 135 Trial primary completion date: Dec 2015 --> Dec 2016
- Oclaiz (octreotide subcutaneous depot) / Camurus
Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Mar 15, 2016
P2, N=24, Active, not recruiting, Sponsor: Camurus AB
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Feb 2016 --> May 2016
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Feb 23, 2016
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2016 --> May 2016 Trial primary completion date: Feb 2016 --> Jun 2016
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Dec 9, 2015
P1, N=27, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2016 --> Jun 2016 N=19 --> 27
- | Oclaiz (octreotide subcutaneous depot) / Camurus
Enrollment closed, Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Nov 27, 2015
P2, N=24, Active, not recruiting, Sponsor: Camurus AB
N=19 --> 27 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Feb 2016
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
Trial completion, Enrollment change, Trial primary completion date, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 6, 2015
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Feb 2016 Active, not recruiting --> Completed | N=60 --> 21 | Trial primary completion date: Sep 2015 --> Jan 2014
- Trial termination: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (clinicaltrials.gov) - Oct 3, 2015
P2, N=7, Terminated, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | N=60 --> 21 | Trial primary completion date: Sep 2015 --> Jan 2014 Completed --> Terminated; Slow accrual
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015
P1, N=43, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Slow accrual Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 17, 2015
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Dec 2015
- Trial completion, Enrollment change, Trial primary completion date: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (clinicaltrials.gov) - Jul 9, 2015
P2, N=7, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Aug 2015 --> Dec 2015 Active, not recruiting --> Completed | N=75 --> 7 | Trial primary completion date: Aug 2011 --> Jan 2011
- Oclaiz (octreotide subcutaneous depot) / Camurus
Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Jun 11, 2015
P2, N=24, Recruiting, Sponsor: Camurus AB
Active, not recruiting --> Completed | N=75 --> 7 | Trial primary completion date: Aug 2011 --> Jan 2011 Trial primary completion date: Apr 2015 --> Oct 2015
- | motesanib (AMG 706) / Takeda
Trial completion, Trial primary completion date: AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors (clinicaltrials.gov) - Jun 4, 2015
P2, N=46, Completed, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: Apr 2015 --> Oct 2015 Active, not recruiting --> Completed | Trial primary completion date: Nov 2012 --> Oct 2014
- || vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 19, 2015
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial primary completion date: Nov 2012 --> Oct 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- ||||| Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Enrollment closed: TELECAST: Telotristat Etiprate for Carcinoid Syndrome Therapy (clinicaltrials.gov) - Apr 9, 2015
P3, N=100, Active, not recruiting, Sponsor: Lexicon Pharmaceuticals
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 3, 2015
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Sep 2015
- ||||| Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Enrollment closed: TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) (clinicaltrials.gov) - Feb 19, 2015
P3, N=105, Active, not recruiting, Sponsor: Lexicon Pharmaceuticals
Trial primary completion date: Feb 2015 --> Sep 2015 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Feb 10, 2015
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Aug 2015
- | Oclaiz (octreotide subcutaneous depot) / Camurus
Enrollment open: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Jan 26, 2015
P2, N=24, Recruiting, Sponsor: Camurus AB
Trial primary completion date: Mar 2015 --> Aug 2015 Not yet recruiting --> Recruiting
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment change, Trial termination: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome (clinicaltrials.gov) - Jan 12, 2015
P2, N=2, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting N=20 --> 2 | Completed --> Terminated; Slow accrual
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jan 2, 2015
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=20 --> 2 | Completed --> Terminated; Slow accrual Recruiting --> Active, not recruiting
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 9, 2014
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Feb 2015
- | Oclaiz (octreotide subcutaneous depot) / Camurus
New P2 trial: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Nov 24, 2014
P2, N=24, Not yet recruiting, Sponsor: Camurus AB
- sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Nov 17, 2014
P2, N=93, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Feb 2015 Active, not recruiting --> Completed
- |||| Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Trial primary completion date: TELECAST: Telotristat Etiprate for Carcinoid Syndrome Therapy (clinicaltrials.gov) - Nov 11, 2014
P3, N=100, Recruiting, Sponsor: Lexicon Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Mar 2016
- |||| Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Trial primary completion date: TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) (clinicaltrials.gov) - Nov 10, 2014
P3, N=105, Recruiting, Sponsor: Lexicon Pharmaceuticals
Trial primary completion date: Jan 2015 --> Mar 2016 Trial primary completion date: Apr 2015 --> Mar 2016
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Enrollment change, Trial primary completion date: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome (clinicaltrials.gov) - Oct 28, 2014
P2, N=20, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Apr 2015 --> Mar 2016 Active, not recruiting --> Completed | N=30 --> 20 | Trial primary completion date: Apr 2018 --> Aug 2014
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 17, 2014
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=30 --> 20 | Trial primary completion date: Apr 2018 --> Aug 2014 Trial primary completion date: Aug 2014 --> Nov 2014
- Enrollment closed: Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Aug 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Phase classification: P1/2 --> P1
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment closed: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome (clinicaltrials.gov) - Sep 28, 2014
P2, N=30, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Phase classification: P1/2 --> P1 Recruiting --> Active, not recruiting
- ||||||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Trial primary completion date, Metastases: RADIANT-2: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (clinicaltrials.gov) - Sep 4, 2014
P3, N=429, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2010
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial suspension: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 16, 2014
P2, N=299, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2010 Recruiting --> Suspended
- | Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Trial completion, Trial primary completion date: Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy (clinicaltrials.gov) - Jul 15, 2014
P2, N=23, Completed, Sponsor: Lexicon Pharmaceuticals
Recruiting --> Suspended Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2014
- Trial termination: Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer (clinicaltrials.gov) - Jul 2, 2014
P1, N=35, Terminated, Sponsor: Yale University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2014 Active, not recruiting --> Terminated